Andrew Cheng - 27 Jun 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President and CEO, Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
27 Jun 2023
Net transactions value
+$24,600
Form type
4
Filing time
27 Jun 2023, 19:12:06 UTC
Previous filing
15 Jun 2023
Next filing
06 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $24,600 +40,000 +9.8% $0.6150* 447,680 27 Jun 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -40,000 -25% $0.000000 117,212 27 Jun 2023 Common Stock 40,000 $0.6150 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are vested and currently exercisable.